Page 26 - John Sims News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday. Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease — after the recently approved…

New research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening — by about four to seven months — but comes with safety risks.

Paul Lindsay from Nottingham said subtle signs like his dad giving money away, 'deep conversations' and losing items were the first signs of Alzheimer's years before the official diagnosis.

Eli Lilly's experimental Alzheimer's drug donanemab​ can modestly slow the worsening of the disease by about four to seven months, according to researchers.

WASHINGTON (AP) — Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.